Equillium (NYSE:EQ) Research Coverage Started at HC Wainwright

Share on StockTwits

HC Wainwright assumed coverage on shares of Equillium (NYSE:EQ) in a research report sent to investors on Friday morning, AnalystRatings.com reports. The firm issued a buy rating and a $14.00 target price on the stock.

Separately, Zacks Investment Research upgraded Flagstar Bancorp from a hold rating to a buy rating and set a $38.00 price target on the stock in a research note on Monday, July 8th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $17.75.

NYSE EQ opened at $5.50 on Friday. The firm’s 50 day moving average price is $5.98. Equillium has a one year low of $5.12 and a one year high of $19.69.

Equillium (NYSE:EQ) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04).

A number of hedge funds and other institutional investors have recently modified their holdings of EQ. American International Group Inc. purchased a new position in Equillium during the fourth quarter valued at approximately $28,000. Deutsche Bank AG purchased a new position in Equillium during the fourth quarter valued at approximately $54,000. Partner Investment Management L.P. purchased a new position in Equillium during the fourth quarter valued at approximately $64,000. Geode Capital Management LLC purchased a new position in Equillium during the fourth quarter valued at approximately $143,000. Finally, Northern Trust Corp purchased a new position in Equillium during the fourth quarter valued at approximately $298,000.

About Equillium

Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.

Featured Article: Buy-Side Analysts

Analyst Recommendations for Equillium (NYSE:EQ)

Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.